title: Novel approaches to pulmonary fibrosis.
abstract: Idiopathic pulmonary fibrosis (IPF) is a devastating condition with a poor prognosis and few treatment options. However, recent research into this condition has led to considerable insights into the pathophysiology of the disease, resulting in the identification of potential biomarkers to aid diagnosis and stratification of patients and the development of novel therapies. In this review we will discuss the recent developments in this field and review how this knowledge has been translated into clinical trials and a paradigm shift in our approach to patients with IPF.
authors.affiliation: Centre for Respiratory Research, University of Nottingham, Nottingham, UK gisli.jenkins@nottingham.ac.uk.
authors.forename: Gisli
authors.initials: G
authors.lastname: Jenkins
authors.affiliation: Nottingham University Hospitals NHS Trust, Nottingham, UK.
authors.forename: Amanda
authors.initials: A
authors.lastname: Goodwin
mesh_terms: D015415:Biomarkers; D006801:Humans; D054990:Idiopathic Pulmonary Fibrosis / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D007211:Indoles; D011728:Pyridones
chemical_list: D015415:Biomarkers; D007211:Indoles; D011728:Pyridones; C093844:pirfenidone; C530716:nintedanib
keywords: Idiopathic pulmonary fibrosis; biomarkers; nintedanib; pirfenidone